Prospective Familial Registry for Pancreas Research (PARTNER)

January 13, 2026 updated by: Mayo Clinic

Prospective Familial Cohort for Pancreas Research

The purpose of this research is to develop a resource registry of individuals currently without pancreatic cancer but are members of a kindred with two or more blood-related family members with pancreas cancer.

Study Overview

Status

Enrolling by invitation

Conditions

Detailed Description

If you agree to be in the study, you will be asked to fill out a questionnaire once every two years. The questionnaire will ask you questions about your health and family history. The investigator may ask you to donate a one-time blood specimen of approximately 3½ tablespoons, which can be done at your local doctor's office. The investigator may ask you if you are willing to provide the names and addresses of other family members who may be eligible to participate in the study. No visits to Mayo Clinic are required for your participation.

Study Type

Observational

Enrollment (Estimated)

3000

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • United States
    • Minnesota
      • Rochester, Minnesota, United States, 55905
        • Mayo Clinic

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Sampling Method

Non-Probability Sample

Study Population

US citizens who meet eligibility requirements

Description

Inclusion Criteria:

  1. An individual who was previously enrolled in Mayo Clinic IRB # 1197-00, 354-06, 355-06, or 19-010791
  2. Is age 18 years or older.
  3. Has a valid United States mailing address.
  4. Has at least two blood-related relatives who have had pancreas cancer or has a blood-relative with pancreatic cancer and that relative carries a known germline mutation in APC, ATM, BRCA1, BRCA2, CDKN2A, EPCAM, MLH1, MSH2, MSH6, PALB2, PMS2, STK11, TP53 or mutations in other genes known to be associated with pancreatic cancer.

Exclusion Criteria:

  1. An individual who is a prison inmate
  2. An individual who is not compos mentis (of sound mind, memory, and understanding), and not able to give consent.
  3. Has personal history of pancreas cancer.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Family history of pancreas cancer
Prospective cohort of individuals who do not have pancreas cancer but are members of a kindred with two or more blood-related family members with pancreas cancer, or with at least one blood-related family member with pancreas cancer and one relative who carries a variant in a gene known to be associated with pancreatic cancer.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
To establish a prospective cohort of individuals from pancreas cancer families
Time Frame: 25 years
To establish and actively follow a resource registry of individuals currently without pancreatic cancer but are members of a kindred with two or more blood-related family members with pancreas cancer.
25 years
Change in health
Time Frame: 25 years
Participants will be asked to complete a health questionnaire every 2 years to ascertain new cancer diagnosis in the subject and in first-degree relatives.
25 years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Mayo Clinic

Investigators

  • Principal Investigator: Samuel Antwi, Ph.D., Mayo Clinic

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 5, 2026

Primary Completion (Estimated)

November 1, 2040

Study Completion (Estimated)

November 1, 2040

Study Registration Dates

First Submitted

January 5, 2026

First Submitted That Met QC Criteria

January 13, 2026

First Posted (Actual)

January 22, 2026

Study Record Updates

Last Update Posted (Actual)

January 22, 2026

Last Update Submitted That Met QC Criteria

January 13, 2026

Last Verified

January 1, 2026

More Information

Terms related to this study

Keywords

Other Study ID Numbers

  • 25-002416

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Family History of Pancreas Cancer

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Paraguay

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe